Notable 52-Week Highs and Lows 9/16: (INTC) (AERI) (CRUS) High; (NVAX) (CXRX) (CSIQ) Low

September 16, 2016 2:19 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

52-Week High:
  • Intel Corporation (Nasdaq: INTC) $38.05. Intel announced that third-quarter revenue is expected to be above the company's previous outlook. The company now expects third-quarter revenue to be $15.6 billion, plus or minus $300 million, as compared to the previous range of $14.9 billion, plus or minus $500 million. The increase in revenue is primarily driven by replenishment of PC supply chain inventory. The company is also seeing some signs of improving PC demand. (The Street was looking for Q3 revenue of $14.9 billion.)

  • Aerie Pharmaceuticals, Inc. (Nasdaq: AERI) $35.25. Aerie Pharmaceuticals announced the pricing of a registered underwritten public offering of $75 million of shares of its common stock at a price to the public of $29.50 per share, before deducting underwriting discounts and commissions and other estimated offering expenses. The offering was upsized by $25 million over the offering amount anticipated to be sold as previously announced. This is in addition to $50 million raised separately through the completion and full utilization of an at-the-market (ATM) program with Cantor Fitzgerald & Co. filed prior to market open on September 15, 2016. Total gross proceeds raised through these offerings were $125 million.

  • Cirrus Logic (Nasdaq: CRUS) $55.68. Cirrus Logic gaining on the back of Apple iPhone 7/7+ news this week.
52-Week Low:
  • Novavax, Inc., (Nasdaq: NVAX) $1.16. Novavax announced topline data from two clinical trials of its RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) in older adults. The Resolve trial, a Phase 3 trial of our RSV F Vaccine in 11,856 older adults (60 years of age and older), did not meet the pre-specified primary or the secondary efficacy objectives, and did not demonstrate vaccine efficacy. Consistent with our previous clinical experience, the vaccine was well tolerated.

  • Concordia International Corp. (Nasdaq: CXRX) $4.80. Concordia International commented on the UK's Health Service Medical Supplies (Costs) Bill, which was introduced into the House of Commons on September 15, 2016. The proposed bill would amend and extend existing provisions of the National Health Service Act 2006 to help manage the cost of health service medicines. Concordia reaffirmed its full year 2016 guidance and confirmed that it believes it has access to sufficient financial resources to manage its liabilities.

  • Canadian Solar Inc. (Nasdaq: CSIQ) $11.74. Canadian Solar lower along with solar-segment peers today. The stock fell as much as 3.3 percent.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Special Reports

Related Entities

Cantor Fitzgerald

Add Your Comment